Trends from subgroup analyses, which tend to be underpowered, also suggest that multidomain interventions might lower cognitive decline or dementia incidence in apolipoprotein E (APOE) ε4 carriers, a well‐established genetic risk factor for late onset Alzheimer's disease (AD), or in individuals with untreated hypertension.4, 5, 12, 13, 14. This evidence concerns the gene APOE and dementia.